Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NN5401 vs insulin glargine in insulin-naive subjects with type 2 diabetes
2009-011271-78Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c at 26 weeks (primary). Started Jul 2009; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-011271-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011271-78.